1. Coronavirus disease (COVID-19) – World Health Organization. Who.int. Accessed July 6, 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. Sukaina M, Hasan MM, Essar MY. Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection. Ann Med Surg (Lond). 2022;79(103941):103941. doi:10.1016/j.amsu.2022.103941
3. Zou R, Peng L, Shu D, et al. Antiviral efficacy and safety of molnupiravir against Omicron variant infection: A randomized controlled clinical trial. Front Pharmacol. 2022;13:939573. doi:10.3389/fphar.2022.939573
4. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509-520. doi:10.1056/NEJMoa2116044
5. Siddiqui A, Adnan A, Abbas M, Taseen S, Ochani S, Essar MY. Revival of the heterologous prime-boost technique in COVID-19: An outlook from the history of outbreaks. Health Sci Rep. 2022;5(2):e531. doi:10.1002/hsr2.531
6. Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 trial of molnupiravir for treatment of covid-19 in nonhospitalized adults. NEJM Evid. 2022;1(2). doi:10.1056/evidoa2100043
7. Fischer WA 2nd, Eron JJ Jr, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430. doi:10.1126/scitranslmed.abl7430
8. Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021;76(12):3286-3295. doi:10.1093/jac/dkab318
9. Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5). doi:10.1128/AAC.02428-20
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(jul21 1):b2700. doi:10.1136/bmj.b2700
11. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. doi:10.1002/14651858.ED000142
12. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. Cochrane.org. Accessed July 6, 2023. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557
14. Arribas JR, Bhagani S, Lobo SM, et al. Randomized trial of molnupiravir or placebo in patients hospitalized with covid-19. NEJM Evid. 2022;1(2). doi:10.1056/evidoa2100044
15. Pitre T, Van Alstine R, Chick G, et al. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. CMAJ. 2022;194(28):E969-E980. doi:10.1503/cmaj.220471
16. Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. Viruses. 2022;14(8):1706. doi:10.3390/v14081706
17. Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022;54(1):516-523. doi:10.1080/07853890.2022.2034936
18. Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID-19. Front Immunol. 2022;13:855496. doi:10.3389/fimmu.2022.855496
19. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial: A randomized clinical trial. JAMA. 2021;325(7):632-644. doi:10.1001/jama.2021.0202
20. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. bioRxiv. Published online 2021:2021.06.15.21258542. doi:10.1101/2021.06.15.21258542